100
Participants
Start Date
May 8, 2017
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
lurasidone
Atypical Antipsychotic
Placebo
Inactive substance
University Hospitals Cleveland Medical Center, Cleveland
The Brigham and Women's Hospital, Department of Psychiatry, Boston
UBC Mood Disorders Center, Vancouver
Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu
Department of Neuropsychiatry, Kansai Medical University, Moriguchi-shi
Department of Psychiatry, Hokkaido University Graduate School of Medicine, Kita-ku
National Center of Neurology and Psychiatry, Kodaira
Department of Psychiatry, Fujita Health University School of Medicine, Aichi
Institute of Psychiatry, Psychology and Neuroscience,King's College London, London
Lakshmi N Yatham
OTHER